DrMedHealth Review
Appears to have shut downDrMedHealth is closed and is not taking new patients. It charged from $199 a month.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
DrMedHealth is no longer taking new patients. This program appears to have shut down, so we're not linking to it. Here are the top-rated GLP-1 providers we recommend instead.
Last published price before it closed: $199/mo. No longer offered.
See our top-rated GLP-1 providers →DrMedHealth sold compounded semaglutide and tirzepatide by telehealth. It no longer does. In October 2026 its domain was an AI health-assistant directory, every former treatment page served that directory, and its legal page called the GLP-1 program “our former telehealth service”.
Vetted alternatives to DrMedHealth
Embody
Best for: a flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies
Editorial score · methodology
Collective
Best for: flat any-dose pricing, if you can absorb a $199 annual membership on top
Editorial score · methodology
AgelessRx
Best for: microdosed compounded GLP-1s from a longevity clinic, or brand Wegovy at manufacturer pricing plus monitoring
Editorial score · methodology
DrMedHealth at a glance
- Status
- Closed: not taking new patients
- Type
- GLP-1 telehealth provider
- Medications
- Compounded semaglutide, Compounded tirzepatide
- Last published price
- $199/mo
- What it included
- Medication · Consult · Shipping
- FDA status
- 1 FDA warning letter (details below)
How DrMedHealth scores
DrMedHealth has closed. These scores describe what it published when we last checked it, before it stopped taking patients.
Six columns, each one computed from something DrMedHealth published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where a seller keeps something back, such as its price or its pharmacy, the score reflects it. Every seller we review goes through the same six columns.
Value25%
3.0/10The listed figure is not a comparable monthly price for a named GLP-1 (it may be a membership fee, an insured copay, a per-vial rate or a starting-dose price), so Value is capped rather than scored against other sellers.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10A price is shown before the questionnaire starts.
Trust & Safety15%
3.5/10The FDA has issued it a warning letter. No pharmacy is named for its prescriptions. It shows a price before asking for health information.
Accessibility10%
5.0/10No state list is available to check, so this is held at the midpoint rather than scored on reach.
Support10%
7.0/10The price covers the medication, clinician visits and shipping.
A seller that shows no price until after the medical intake loses points on User Experience and Trust & Safety, and its review says so. How we score →
What we checked on DrMedHealth
Last checked August 2026- Checked the listed price across 2 dose or plan tiers
- Checked what the monthly price covers, and what it leaves out
- Checked FDA warning letters for DrMedHealth
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below.
Medications DrMedHealth listed
DrMedHealth listed compounded semaglutide and compounded tirzepatide. Each one has its own guide: how it works, the dosing schedule, the side effects that show up in practice, and what the trials measured.
Prices it published before closing
Prices re-verified
In its favor
- Showed its price before the medical questionnaire, so you could compare it without handing over health information
- The monthly price included the medication, clinician visits and shipping
Against it
- The FDA has issued DrMedHealth a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
DrMedHealth is no longer taking new patients. What follows describes the program as it last ran, for anyone comparing it with a seller that is still open.
What DrMedHealth charged
DrMedHealth charged $199/month.
- Compounded semaglutide: $199/month
- Compounded tirzepatide: $299/month
Belle Health, at about $199/month, is the closest like-for-like alternative we review.
What DrMedHealth dispensed
DrMedHealth prescribed semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two best-evidenced weight-loss molecules currently on the market. The medication is compounded rather than dispensed as an approved pen. Compounding serves real clinical needs and is entirely lawful; what it is not is reviewed, and the cost difference reflects that.
Safety and disclosure
DrMedHealth told buyers its price before the medical questionnaire. The FDA has issued DrMedHealth a warning letter, summarized at the top of this page. A letter flags a problem rather than ruling a seller out, so read what it says before deciding what it means for you. How we weigh oversight, disclosure and price is set out in our scoring methodology.
Our read
DrMedHealth is no longer taking new patients, so the choice is among the sellers that are still open. Whatever you decide, read the warning letter summarized at the top of this page first, and raise it with the clinician who would prescribe for you.
The Bottom Line
DrMedHealth is closed and is not taking new patients. It charged from $199 a month.
Where DrMedHealth is the wrong choice
No seller suits every reader, and pretending otherwise is the easiest way to sell one. On these three counts, another seller does better.
- If you need the FDA-approved pen rather than a compounded vial, consider WellMedRx.
- If the standing monthly cost is what decides it, consider Collective (from $59/mo + membership).
- If you want a human checking in, not just a prescription, consider Eden.
If none of these fits, our guide to alternatives to DrMedHealth sets more sellers in the same category beside DrMedHealth on price, states and what the price includes.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Regulatory notice
DrMedHealth has an FDA warning letter on record, dated June 8, 2026
This letter concerns false & misleading claims/misbranded (telehealth). A warning letter is public correspondence from FDA, not an adjudication. On its own it establishes no finding of illegal activity, and a company that gets one often answers with corrective action.
Sources
Cited across this DrMedHealth review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Aronne LJ et al.)— New England Journal of Medicine.PMID: 40353578.